Compare Fubotv Inc (FUBO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Summit Therapeutics Inc — how do they compare? Fubotv Inc trades at $10.39 (market cap $302.39M), while Summit Therapeutics Inc trades at $14.11 (market cap $11.70B). The key difference: Summit Therapeutics Inc is far larger — about 38.7× Fubotv Inc's market cap. Which is the better fit depends on your goals.
| FUBO | SMMT | |
|---|---|---|
Market Cap | $302.39M | $11.70B |
Sector | Technology | Health |
52-Week High | $54.72 | $29.32 |
52-Week Low | $8.09 | $13.05 |
Enterprise Value | $472.81M | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $10.46, up 9.64% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals, with revenue reaching $1.62B in 2024 and a projected net profit of $123M in 2025. Recent CEO appointment of former Disney+ executive Alisa Bowen has driven positive sentiment, while valuation ratios like P/E of 2.67 and P/S of 0.21 appear attractive relative to historical norms.
The outlook for FUBO is cautiously optimistic, with upside to the $16.25 consensus price target, but risks include persistent cash flow challenges and intense streaming competition. Investors should weigh the potential for profitability growth against execution risks in a crowded market.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
